Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03263052 · ClinicalTrials.gov registry record
Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 40
- Enrollment target
NCT03263052: Completed study, sponsored by University of Illinois at Chicago.
NCT03263052 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03263052 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study will investigate whether converting patients from FDA approved immediate-release tacrolimus to FDA approved extended release tacrolimus (Envarsus) reduces neurological side-effects, improves quality of life, and enhances adherence. A select group of elderly (\> 60 years of age) patients, who are especially sensitive to tacrolimus-related adverse (AEs) effects, will be provided the opportunity to convert to Envarsus with this study.
Primary Outcome
Mean change in QOL scores from baseline to day 14 and day 28 after conversion from tacrolimus to Envarsus.
Interventions
- DRUG Tacrolimus XR (Envarsus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2020-01-01 |
What the finished NCT03263052 record still lists
NCT03263052 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus XR (Envarsus) is the first listed.
NCT03263052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03263052 about?
NCT03263052 is a clinical study titled "Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL". This study will investigate whether converting patients from FDA approved immediate-release tacrolimus to FDA approved extended release tacrolimus (Envarsus) reduces neurological side-effects, improves quality of life, and enhances adherence. A select group of elderly (\> 60 years of age) patients, ...
What is the current status of trial NCT03263052?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2017-07-01. Estimated completion is 2020-01-01.
What interventions are being tested in trial NCT03263052?
The interventions under investigation include: Tacrolimus XR (Envarsus) (DRUG).
Who is sponsoring clinical trial NCT03263052?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI